MAP2K2 F57C

CI-VAR-00001125Explore in graph →CIViC 1398 rs121434497

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Melanoma1
MAP2K2 F57C	Vemurafenib	Predictive	C	Supports Sensitivity Response	—	submitted	EID4030 In a retrospective study of 30 metastatic melanoma patients, a patient harboring MAP2K2 F57C mutation was reported to be resistant to vemurafenib treatment. The patient was initially found to harbor a… (full text at CIViC) PMID 24463458 · Rizos et al., 2014 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.